The finding that the transgene expression driven by the EF1α promoter is robust enough to confer puromycin resistance and drive GFP expression is valuable for other researchers and may have significant implications for transgene therapy in AML. The gene discussed is EEF1A1; the disease is acute myeloid leukemia.